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Editorial
There are an estimated 240,000 new cases of ovarian cancer
diagnosed worldwide each year [1]. Due to late presentation, in many
parts of the world it remains the most lethal gynecological cancer [2].
In 2004, a new model description of this disease was proposed that
combined both histopathological and molecular features and which
classified epithelial ovarian cancers into two broad categories
designated Type I and Type II tumors [3]. Type I tumors tend to be low
grade and are exemplified by clear cell, mucinous, low-grade serous
and endometrioid histologies with associated molecular alterations
characterised by mutations in genes including HER2, KRAS, BRAF,
CTNNB1, PTEN, PIK3CA, ARIDIA and PPPR1A [3]. More recently,
profiling studies have attempted to further stratify ovarian cancer into
molecular subtypes, although these have largely focused on Type II,
high grade serous ovarian tumors which frequently contain mutations
in p53 and the BRCA genes [3-5]. These genetic abnormalities can help
define the response of cancers to specific treatments, hence the
widespread use of platinum containing drugs which have useful
efficacy particularly in type II disease. Platinum containing regimens
are the standard of care in first line treatment of this disease [2].
However, resistance frequently develops and there is an ongoing need
for improved second line options.
The observation that HER2 is amplified and overexpressed,
especially in clear cell and mucinous tumors suggests possible use of
HER2 based therapies in selected ovarian cancers [6,7]. In fact,
increased expression of HER2 has been observed in small groups of
tumors across all the histological subtypes including Type II disease
[8]. HER2 (or erbB2) is a member of the HER (erbB) family of cell
surface receptors. In breast cancer, 15-20% cancers have amplification
and high expression that enables these tumors to be treated with
HER2-targeted antibodies such as trastuzumab (Herceptin) [9].
In ovarian cancer, trastuzumab was the first HER2 targeted
antibody to be trialled and the phase II trial indicated a response rate
of 7.3% in a cohort of HER2+ cancer patients [10]. In 2006, another
humanised anti-HER2 antibody (pertuzumab, Perjeta) underwent
clinical evaluation in ovarian cancer and this demonstrated clinical
benefit in 14.5% of patients in a monotherapy Phase II trial [11]. These
modest response rates are typical of active second line agents in
ovarian cancer demonstrating the difficulty of treating advance
resistant disease. The pertuzumab monotherapy trial was followed by a
clinical trial of pertuzumab in combination with chemotherapy in a
platinum-resistant group of patients [12]. In this study, there was an
indication of improved benefit when pertuzumab was given alongside
chemotherapy particularly in patients whose tumors had low HER3
mRNA expression levels. These clinical studies support the view that a
subgroup of ovarian cancers do benefit from HER2-targeted treatment,
but it would be helpful to enhance the level of activity further.
Over the last decade, several developments have identified more
effective treatments targeting HER2+ disease for breast cancer. Firstly,
use of the combination of trastuzumab with pertuzumab has
demonstrated superiority of the combination over the single agents in
a large scale Phase III clinical trial (CLEOPATRA) [13]. This lead to
the drug combination being approved for treatment of HER2+
metastatic breast cancer and more recently for neoadjuvant treatment.
Secondly, the antibody-drug conjugate ado-trastuzumab emtansine
(Kadcyla, trastuzumab-DM1) has shown marked activity against
HER2+ breast cancer and has been approved for treatment of HER2+
disease [14]. This is a conjugate of trastuzumab with a cytotoxic moiety
emtansine (DM1) which is particularly effective against tubulin. Ado-
trastuzumab emtansine is now FDA approved for treatment of HER2+
breast cancer disease. These approaches now merit consideration in
ovarian cancer.
Preclinical experimental studies have demonstrated that HER2+
ovarian cancer xenografts are responsive to combination of
trastuzumab and pertuzumab and furthermore, the two antibodies are
more effective together than either one alone, producing very marked
and prolonged growth inhibition [15,16]. Similarly, interesting results
have been obtained for ado-trastuzumab emtansine in preclinical
models of ovarian cancer, again producing marked tumour regression
in experimental models [17,18]. Together, these data support the view
that HER2+ ovarian cancer cells can show strong responsiveness to
these enhanced HER2-targeting strategies in an experimental setting
and merit consideration for future ovarian cancer trials. If these trials
go ahead, it will be important to analyse biomarkers to identify features
of responding tumours. Markers such as HER2 or HER3 expression
levels may be useful to help identify sensitive ovarian cancers and
further biomarkers are currently being sought within preclinical
models [15,16].
In conclusion, these data support continued clinical investigation of
HER2-targeted antibody evaluation in chemotherapy insensitive/
resistant ovarian cancer. The likely limited number of responding
patients will necessitate the need for biomarkers to help predict which
patients are most likely to benefit. If these hurdles can be overcome,
then HER2-targeted antibodies could find a role in the treatment of
selected ovarian cancers.
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